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Summary
Objective: As we previously reported, ADAMTS-7 and ADAMTS-12, two members of ADAMTS (a disintegrin and metalloprotease with throm-
bospondin motifs) family, degrade cartilage oligomeric matrix protein (COMP) in vitro and are signiﬁcantly induced in the cartilage and syno-
vium of arthritic patients [Liu CJ, Kong W, Ilalov K, Yu S, Xu K, Prazak L, et al. ADAMTS-7: a metalloproteinase that directly binds to and
degrades cartilage oligomeric matrix protein. FASEB J 2006;20(7):988e90; Liu CJ, Kong W, Xu K, Luan Y, Ilalov K, Sehgal B, et al.
ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein. J Biol Chem 2006;281(23):15800e8]. The purpose of this study
was to determine (1) whether cleavage activity of ADAMTS-7 and ADAMTS-12 of COMP are associated with COMP degradation in osteo-
arthritis (OA); (2) whether alpha-2-macroglobulin (a2M) is a novel substrate for ADAMTS-7 and ADAMTS-12; and (3) whether a2M inhibits
ADAMTS-7 or ADAMTS-12 cleavage of COMP.
Methods: An in vitro digestion assay was used to examine the degradation of COMP by ADAMTS-7 and ADAMTS-12 in the cartilage of OA
patients; in cartilage explants incubated with tumor necrosis factor-alpha (TNF-a) or interleukin-1-beta (IL-1b) with or without blocking anti-
bodies; and in human chondrocytes treated with speciﬁc small interfering RNA (siRNA) to knockdown ADAMTS-7 or/and ADAMTS-12. Diges-
tion of a2M by ADAMTS-7 and ADAMTS-12 in vitro and the inhibition of ADAMTS-7 or ADAMTS-12-mediated digestion of COMP by a2M were
also analyzed.
Results: The molecular mass of the COMP fragments produced by either ADAMTS-7 or ADAMTS-12 were similar to those observed in OA
patients. Speciﬁc blocking antibodies against ADAMTS-7 and ADAMTS-12 dramatically inhibited TNF-a- or IL-1b-induced COMP degradation
in the cultured cartilage explants. The suppression of ADAMTS-7 or ADAMTS-12 expression by siRNA silencing in the human chondrocytes
also prevented TNF-a- or IL-1b-induced COMP degradation. Both ADAMTS-7 and ADAMTS-12 were able to cleave a2M, giving rise to 180-
and 105-kDa cleavage products, respectively. Furthermore, a2M inhibited both ADAMTS-7- and ADAMTS-12-mediated COMP degradation in
a concentration (or dose)-dependent manner.
Conclusion: Our observations demonstrate the importance of COMP degradation by ADAMTS-7 and ADAMTS-12 in vivo. Furthermore, a2M is
a novel substrate for ADAMTS-7 andADAMTS-12.More signiﬁcantly, a2M represents the ﬁrst endogenous inhibitor of ADAMTS-7andADAMTS-12.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Abbreviations: COMP cartilage oligomeric matrix protein, ADAMTS a disintegrin and metalloproteinase with thrombospondin motifs, MMPs
matrix metalloproteinases, PCR polymerase chain reaction, TSP thrombospondin, TNF-a tumor necrosis factor-alpha, IL-1b interleukin-
1-beta, GAPDH glyceraldehyde-3-phosphate dehydrogenase, SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis, OA
osteoarthritis, RA rheumatoid arthritis, a2M a2-Macroglobulin.Introduction
Cartilage consists mainly of extracellular matrix (ECM) with
very few cells, mostly chondrocytes. Arthritis is characterizedaThese authors contributed equally to this paper.
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1413by the breakdown of the ECM and subsequent loss of artic-
ular cartilage typically mediated by an excessive amount of
active proteolytic activity1. The ECM is a network of proteins
and macromolecules that provides both strength and nutri-
ents for the cells. Articular cartilage is composed of
60e85% water, 15e22% type II collagen, 4e7% aggrecan
and less than 5% other matrix proteins such as cartilage
oligomeric matrix protein (COMP), decorin and collagens I,
V, VI, IX, and XI among others. COMP, a prominent non-
collagenous component of cartilage, accounts for approxi-
mately 1% of the wet weight of articular tissue2,3. COMP is
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coprotein composed of approximately equal subunits
(w110 kDa each)4,5. COMP fragments have been detected
in the cartilage, synovial ﬂuid, and serum of patients with
knee injuries, osteoarthritis (OA) and rheumatoid arthritis
(RA)6e8. In previous studies to identify the physiological en-
zymes responsible for COMP degradation, we performed
a functional genetic screen, which led to the isolation of a dis-
integrin and metalloprotease with thrombospondin motifs
(ADAMTS)-7 and ADAMTS-12 as COMP-binding part-
ners9,10. Subsequent studies showed that both ADAMTS-7
and ADAMTS-12 were able to digest COMP in vitro and
that their levels were signiﬁcantly upregulated in arthritic
cartilage and synovium compared to a normal controls6e10.
ADAMTS-7 and ADAMTS-12 belong to the metalloprotei-
nase ADAMTS family. The ADAMTS family consists of se-
creted zinc metalloproteinases with a precisely ordered
modular organization that includes at least one thrombo-
spondin (TSP) type I repeat11. So far, 19 members have
been cloned in this family and some of them have known
functions that have been implicated in speciﬁc diseases12.
For instance, ADAMTS-13 mutants have a role in throm-
botic thrombocytopenic purpura, a disease characterized
by a decrease in the amount of circulating platelets13. Muta-
tions in the ADAMTS-2 gene (procollagen I N-proteinase)
cause Ehlers-Danlos syndrome Type VII C, a genetic con-
dition characterized by defects in collagen synthesis, as
well as bovine dermatopraxis14. A number of ADAMTS
members have been implicated in the breakdown of carti-
lage in OA and RA, including ADAMTS-4 (aggrecanase
1), ADAMTS-5 (aggrecanase 2)15e18, ADAMTS-79 and
ADAMTS-1210.
a2-Macroglobulin (a2M) is a member of the a-macroglob-
ulin family of proteins found in the circulation of a broad
range of species19. Human a2M is found at relatively high
levels (2e4 mg/ml) in plasma and is a tetramer of four iden-
tical 185-kDa subunits, each of which has an exposed 39-
amino acid ‘‘bait region’’ that contains cleavage sites for
a variety of proteinases20,21. The function of the bait region
is to trap the proteinase, potentially accounting for its capac-
ity to bind and inhibit ADAMTS-4, ADAMTS-5 and
ADAMTS-1022,23. ADAMTS-1 forms a stable complex with
a2M that is dependent on the zinc binding catalytic domain
of ADAMTS-124.
Inhibitionof degradative enzymescanslowor blockdisease
progression. The isolation of physiological inhibitors for the
cartilage degradative enzymes is, therefore, of great interest
from both a pathophysiological and a therapeutic standpoint.
a2M isan inhibitor of severalmetalloproteases, including colla-
genase, stromelysis25, ADAMTS-4 and ADAMTS-523. In
addition, a2Malso associateswithADAMTS-7
26. The purpose
of the study was to examine the potential association of the
ADAMTS-7 and ADAMTS-12-mediated cleavage of COMP
with OA damage, and the possible role of a2M as a substrate
for and inhibitor of ADAMTS-7 orADAMTS-12enzymeactivity
against COMP.Materials and methodsSOURCES OF TISSUESNormal adult articular cartilage was obtained from the knees of patients
(mean age 56.7 years, range 43e64 years) who had died of diseases
unrelated to arthritis (specimens obtained en bloc from the Musculoskeletal
Transplant Foundation). The grade of OA was determined using the
KellgreneLawrence Grading System27. Normal cartilage samples were
without radiographic or intra-articular evidence of arthritic disease
(KellgreneLawrence Grade 0). Arthritic cartilages were obtained (with IRB#:12758) from patients undergoing elective total knee arthroplasty for end-stage
OA with KellgreneLawrence Grade of 3 or 4 from the distal femora of eight
patients (mean age 58.4 years, range 49e66 years). The samples were
then stored at 80C until analysis.IN VITRO DIGESTION ASSAY OF COMP BY ADAMTS-7 AND
ADAMTS-12An in vitro digestion protocol described previously9,10 was followed to de-
termine whether the fragments resulted from COMP digestion by ADAMTS-7
and ADAMTS-12 are the same as those seen in the cartilage of OA patients.
Brieﬂy, puriﬁed COMP was incubated with either recombinant ADAMTS-7 or
ADAMTS-12 in a digestion buffer (50-mM TriseHCl, 100-mM NaCl, 5-mM
CaCl2, 2-mM ZnCl2, pH 7.5) for 8 h at 37
C. The digested products were re-
solved by 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE), under reduced condition, and the gel was stained with Coo-
massie brilliant blue G-colloidal solution.CARTILAGE EXPLANT CULTURESHuman cartilage was cultured as described previously28,29 with modiﬁca-
tions. Brieﬂy, human knee cartilage was dissected into pieces of diameter
of approximately 4 mm by punches of 1- to 2-mm thickness. The cartilage
was dispensed into tissue-culture ﬂasks (0.7 g/ﬂask) and incubated over-
night in control, serum-free medium Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA) containing 25-mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 2-mM glutamine, 100-mg/ml strep-
tomycin, 100-IU/ml penicillin, 2.5-mg/ml gentamicin, and 40-units/ml nystatin.
Fresh control medium (10 ml) with tumor necrosis factor-alpha (TNF-a, 5 ng/
ml) or interleukin-1-beta (IL-1b, 5 ng/ml) (in triplicate for statistical analysis)
was then added (day 0). At day 2, the supernatants were harvested for
COMP degradation analysis by Western blotting and the cartilage samples
were extracted for RNA, as described below. In some cultures, antibodies
against ADAMTS-7 or/and ADAMTS-12 (5 mg/ml of anti-ADAMTS-7 or/and
ADAMTS-12 rabbit polyclonal antibodies) were added9,10. At day 7, culture
supernatants were harvested and COMP degradative fragments in the cul-
ture supernatants were determined using Western blotting assay.COMP DEGRADATION ANALYSES IN THE CARTILAGE
OF OA PATIENTSExtracts of normal and OA cartilages and supernatants from cultured car-
tilage explants were analyzed by Western blotting as previously de-
scribed9,10. Brieﬂy, the samples were loaded on 8% gels and separated by
SDS-PAGE under reducing conditions. Separated proteins were transferred
to polyvinylidene diﬂuoride membranes and probed with a 1:2500 dilution of
rabbit polyclonal anti-COMP antiserum6,9,30,31. Subsequently, membranes
were incubated with a 1:20,000 dilution of goat anti-rabbit IgG horseradish
peroxidase conjugate as the secondary antibody, and the signal detected
using the ECL chemiluminescent system (Amersham Pharmacia Biotech,
Upsala, Sweden).ANALYSIS OF ADAMTS-7 AND ADAMTS-12, mRNA
IN CULTURED CARTILAGE EXPLANTSTotal RNA was extracted as described previously9,10 and real-time poly-
merase chain reaction (PCR) was performed using a sequence-speciﬁc
probe and primers for ADAMTS-7 (ﬂuorescence-labeled oligonucleotide
probes [using 6-carboxy-ﬂuorescein (FAM)] probe: 50-AAGCGCTT
CCGCCTCTGCAACC-30; primers: 50-CAGCCTACGCCCAAATACAAA-30
and 50-CCCTTGTAGAGCATAGCGTCAAA-30) and ADAMTS-12 (ﬂuores-
cence-labeled oligonucleotide probes [using FAM] probe: 50-AGGA
CATCTGTGCTGGTTTCAATCGCC-30; primers: 50-CACGACGTGGCTG
TCCTTCT-30 and 50-CCGAATCTTCATTGATGTTACAACTG-30). The PCR
products obtained was conﬁrmed by direct sequencing of the amplicons. A
standard curve with copy numbers ranging from 103 to 109 was produced us-
ing human cartilage cDNA as the template. An XY scatter plot was produced
using Microsoft Excel software, and the equation y¼mxþ b (where m¼ the
slope of the standard curve and b¼ the y intercept of that line) was calcu-
lated and R2 values obtained. As an internal control, 18S rRNA was analyzed
in parallel by using the Endogenous Control Human rRNA kit (Applied Bio-
systems, Foster City, CA).
PCR reactions for all samples were performed in duplicate in 96-well op-
tical plates with 5 ng of cDNA (1 ng of cDNA for the 18S rRNA), 100-nM
probe, 200-nM each primer, and 10.0 ml of TaqMan Universal 2 PCR Mas-
ter Mix (PE-Applied Biosystems, St. Louis, MO) in a 20-ml reaction volume.
The ampliﬁcation reaction was carried out over 40 cycles (an initial holding
stage of 2 min at 50C and then 10 min at 95C, followed by a two-step
cycling program of 15 s at 95C and 1 min at 60C).
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SMALL INTERFERING RNA (siRNA)The human chondrocyte cell line, C-28/12, was used as a model for ana-
lyzing the efﬁciency of knockdown by the siRNAs and for determining the con-
sequences of knockdown of ADAMTS-7 and ADAMTS-12 on COMP
degradation. Thecellsweremaintained inDMEMsupplementedwith 10% fetal
bovine serum (FBS). Two regions of human ADAMTS-7 or/and ADAMTS-12
were targeted for siRNA using mammalian expression pSUPER vector (Oli-
goEngine, Seattle, WA) according to the manufacturer’s instructions. To gen-
erate each siRNA, equimolar amounts of complementary sense and antisense
strands weremixed and annealed slowly by cooling to 10C in a 50-ml reaction
buffer (100-mM NaCl and 50-mM HEPES pH 7.4). The annealed oligos were
inserted into the BglII/HindIII sites of pSUPER vector. The resulting plasmids
and control vector pSUPER were co-transfected with the corresponding ex-
pression plasmid into C28I2 cells using LipofectAMINE 2000 reagent (Invitro-
gen, Rockville, MD) and the levels of ADAMTS-7 or/and ADAMTS-12 were
monitored using immumoﬂuorescence cell staining as described below. The
data demonstrated that the siRNA 50-ACCTAAAGATCACGCACCA-30 and
the siRNA 50-ACACATCACACACACCCAA-30 were able to efﬁciently reduce
the expression of human ADAMTS-7 and ADAMTS-12, respectively. The C-
28/12 cells were then transfected with the siRNA described above [i.e.,
ADAMTS-7 siRNA (siTS-7), ADAMTS-12 siRNA (siTS-12), both (siTS-
7þ siTS-12) or pSUPER control (CTR)] and cultured in the presence of
TNF-a (5 ng/ml) or IL-1b (5 ng/ml). After incubation for 7 days, the media
were collected and assayed by Western blotting with anti-COMP antibody.IMMUMOFLUORESCENCE CELL STAININGBrieﬂy, cultures plated on chamber slides (Nalge Nunc International, Na-
perville, IL) were ﬁxed with cold 100% methanol and air-dried. After rehydra-
tion in phosphate buffered saline (PBS) and blocking with 30% goat serum for
30 min, the cells were incubated with primary antibodies against ADAMTS-7
(Santa Cruz; diluted 1:100) or ADAMTS-12 (diluted 1:100) for 1 h. Secondary
antibodies against rabbit IgG conjugated with FITC (Santa Cruz; diluted
1:100) were applied for 45 min, followed by an incubation with 0.5 mg of
49,69-diamidino-2-phenylindole dihydrochloride (DAPI) for 5 min. The spec-
imens were observed under a ﬂuorescence microscope with appropriate op-
tical ﬁlters. Microscopic images were captured using the Image program
(Media Cybernetics, Silver Spring, MD) and an Olympus microscope.DIGESTION ASSAY OF a2M by ADAMTS-7 AND ADAMTS-12
IN VITROTo determinewhether ADAMTS-7 and ADAMTS-12 cleave a2M, increasing
amountsof recombinantADAMTS-7andADAMTS-129,10were incubatedover-
night at 37Cwith 140- or 200-nMhumana2M (Sigma-Aldrich, St. Louis, MO) in
50-mMTriseHCl, pH 7.5, 100-mM NaCl, and 10-mMCaCl2. Subsequently, re-
action products were analyzed by 8% SDS-PAGE under non-reducing condi-
tions and the gel was stained with Coomassie brilliant blue R-250.INHIBITION ASSAYS OF a2M ON ADAMTS-7 OR ADAMTS-12
DIGESTION OF COMPTo test the ability of a2M to inhibit ADAMTS-7 and ADAMTS-12 cleavage of
COMP, recombinant ADAMTS-7 or ADAMTS-12 was preincubated with vari-
ous concentrations of a2M for 2 h at 37
C. Then puriﬁedCOMPwas added into
the above mixture in the digestion buffer (50-mM TriseHCl, 100-mM NaCl, 5-
mM CaCl2, 2-mM ZnCl2, pH 7.5) for two more hours at 37
C. The digested
products were resolved by 8% non-reduced SDS-PAGE gel, and the gel
was either stained with Coomassie brilliant blue G-colloidal solution or
detected using Western blotting with anti-COMP antibody9,10,32.STATISTICAL TESTTwo-sample Student’s t test was used to determine signiﬁcant differences
(P< 0.05) of the levels of ADAMTS-7 and ADAMTS-12 between control and
TNF-a- or IL-1b-treated cartilage explants.Fig. 1. Western blotting analysis of human OA cartilage samples
Resultsand ADAMTS-7 (TS-7)- and ADAMTS-12 (TS-12)-mediated
COMP digestion. Samples were resolved on 8% SDS-PAGE
gels, under reducing conditions, and COMP was detected usingTHE SIZES OF THE COMP FRAGMENTS PRODUCED BY
ADAMTS-7 OR ADAMTS-12 ENZYME ACTIVITY ARE SIMILAR
TO THOSE IN CARTILAGE FROM OA PATIENTS
an anti-COMP antiserum. Intact COMP monomer, 110-kDa frag-
ment and additional fragment in OA cartilage are indicated with
arrows 1, 2, 3, respectively.To elucidate the importance of ADAMTS-7- or ADAMTS-
12-mediated COMP degradation in vivo, we determinedwhether OA cartilage contained the same fragment as we
saw in ADAMTS-7- or ADAMTS-12-mediated COMP diges-
tion in vitro. For this purpose, we analyzed the cartilage
from six OA patients and COMP fragments produced by
in vitro COMP digestion with the recombinant ADAMTS-7
or ADAMTS-12 using Western blotting with anti-COMP an-
tibodies (Fig. 1). An approximately 110-kDa fragment (arrow
2) that was produced by digestion with ADAMTS-12 (lane 1)
and ADAMTS-7 (lane 2) was an abundant component of all
OA cartilage samples (lanes 3e8); intact COMP monomer
was also detected (arrow 1). Interestingly, an additional
fragment (arrow 3) was observed in OA samples that was
absent in the in vitro COMP digestion assay with
ADAMTS-12 and ADAMTS-7, suggesting that additional
enzyme(s) may contribute to COMP degradation in OA
patients. Note that only intact COMP was detected in the
normal cartilage (lane 9).INDUCED EXPRESSION OF ADAMTS-7 AND ADAMTS-12
BY TNF-a AND IL-1bWe next investigated whether TNF-a and IL-1b, two ma-
jor inﬂammatory cytokines that induce the expression of
a number of metalloproteinases involved in the develop-
ment and progression of arthritic diseases33e35, could reg-
ulate the expression of ADAMTS-7 and ADAMTS-12.
Human cartilage explants were cultured in the absence or
presence of either 5 ng/ml of TNF-a or 5 ng/ml of IL-1b for
1 day in serum-free medium and real-time PCR was per-
formed [see Fig. 2(A)]. Both TNF-a and IL-1b induced the
mRNA expression of ADAMTS-7 and ADAMTS-12 com-
pared to untreated cartilage explants.ANTIBODIES AGAINST ADAMTS-7 AND ADAMTS-12 ANTIBODY
DRAMATICALLY INHIBITS TNF-a- OR IL-1b-INDUCED COMP
DEGRADATIONSince both TNF-a and IL-1b upregulate ADAMTS-7 and
ADAMTS-12, two enzymes known to degrade COMP, we
next determined whether these enzymes could account
speciﬁcally for the COMP degradation induced by TNF-a or
IL-1b in the cartilage organ culture system. Since TNF-a and
IL-1b are known to induce the expression of various
Fig. 2. ADAMTS-12 and ADAMTS-7 blocking antibodies inhibit TNF-a- or IL-1b-induced COMP degradation. (A) Upregulation of ADAMTS-7
and ADAMTS-12 by TNF-a and IL-1b. The units are arbitrary and the leftmost bar in each group indicates a relative level of 1. *P< 0.05 vs
untreated controls. (B and C) Antibody blocking assays. OA cartilage explants were cultured in the presence of 5 ng/ml of TNF-a (B) or 5 ng/ml
of IL-1b (C) with blocking antibodies, as indicated, for 7 days. The media were separated on non-reduced SDS-PAGE gels and COMP was
detected using an anti-COMP antibody. Intact COMP and its degradative fragment are indicated with arrow and arrowhead, respectively.
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radation might be due to other enzymes alone or in combina-
tion with ADAMTS-7/ADAMTS-12 rather than to ADAMTS-7/
ADAMTS-12 alone. To determine whether ADAMTS-7 or/
and ADAMTS-12 is directly involved in the COMP degrada-
tion induced by these two proinﬂammatory cytokines, we
compared COMP degradation in the absence or presence
of ADAMTS-12 and/or ADAMTS-7 blocking antibody9
[Fig. 2(B) and (C)]. TNF-a and IL-1b treatments resulted in
a 110-kDa COMP fragment (lane 1, indicated by the arrow-
head). This fragment was reduced in the presence of either
ADAMTS-12 (lane 2) or ADAMTS-7 (lane 3) blocking anti-
body; in addition, COMP degradation was totally blocked
by a combination of these two antibodies and intact COMP
was observed (lane 4, indicated by the arrow), clearly indicat-
ing that ADAMTS-12 andADAMTS-7 are important in TNF-a-
and IL-1b-induced COMP degradation. Note that control
antibody did not show any blocking activity (not shown).Fig. 3. Reduced expression of ADAMTS-7 or/and ADAMTS-12 by siRNA
(A) siRNAs against ADAMTS-7 and ADAMTS-12 efﬁciently suppress the
cence cell staining. Immortalized human chondrocytes, C-28/I2, transfecte
(siTS-7) or pSUPEReADAMTS-12 siRNA (siTS-12) were stained with eith
nuclei were stained with DAPI and the overlapping of these two signals is
and ADAMTS-12 dramatically inhibits COMP degradation. The C-28/1
ADAMTS-12 siRNA (siTS-7), both (siTS-7þ siTS-12) or pSUPER contro
5 ng/ml of Il-1b (C) for 7 days. The media were separated on reduced SD
body. Intact COMP and its degradative fragment are inINHIBITION OF ADAMTS-7 OR/AND ADAMTS-12 EXPRESSION
VIA siRNA-MEDIATED SILENCING PREVENTS COMP
DEGRADATION IN HUMAN CHONDROCYTESTo further verify the importance of ADAMTS-7 and
ADAMTS-12 in degrading COMP in vivo, we ﬁrst sup-
pressed ADAMTS-7 or/and ADAMTS-12 gene expression
in human chondrocytes using the siRNA approach. We
identiﬁed 19-nucleotide gene-speciﬁc sequences for
ADAMTS-7 and ADAMTS-12, respectively, and then gener-
ated pSUPEResiTS-7 and pSUPEResiTS-12 constructs
encoding siRNAs targeting the speciﬁc gene sequences.
Immunoﬂuorescent cell staining with human C-28/I2 chon-
drocytes transfected with either pSUPEResiTS-7, pSU-
PEResiTS-12 or pSUPER vector demonstrated that
expression of the speciﬁc siRNAs efﬁciently reduced the
levels of the corresponding proteins [Fig. 3(A)]. Next we
examined whether the siRNA knockdown of ADAMTS-7
or/and ADAMTS-12 would affect COMP degradation. Thesilencing inhibits the degradation of COMP in human chondrocytes.
expression of their target molecules, assayed by immumoﬂuores-
d with either pSUPER plasmid (CTR), pSUPEReADAMTS-7 siRNA
er anti-ADAMTS-7 (left panel) or anti-ADAMTS-12 (right panel). The
shown as ‘‘merge’’. (B and C) Knockdown of either ADAMTS-7 or/
2 cells were transfected with either ADAMTS-7 siRNA (siTS-7),
l (CTR), were cultured in the presence of 5 ng/ml of TNF-a (B) or
S-PAGE gels and COMP was detected using an anti-COMP anti-
dicated with arrow and arrowhead, respectively.
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PEResiTS-7, pSUPEResiTS-12 or both and cultured with
serum-free medium containing TNF-a or IL-1b for 1 week.
Western blotting with anti-COMP antibody [Fig. 3(B) and
(C)] showed a robust COMP degradative fragment in the
medium from TNF-a- or IL-1b-treated cultures (lane 1).
However, the intensity of the COMP fragment was reduced
in the media collected from the cells transfected with pSU-
PEResiTS-7 or pSUPEResiTS-12 (lanes 2 and 3). Espe-
cially, the degradative fragment was barely detectable
when the cells were co-transfected with pSUPEResiTS-7
and pSUPEResiTS-12 (lane 4). Collectively, these results
further indicated that both ADAMTS-7 and ADAMTS-12
were critical for the TNF-a- or IL-1b-induced COMP
degradation.a2M IS A NOVEL SUBSTRATE FOR ADAMTS-7 AND ADAMTS-12Since a2M associates with ADAMTS-7
26, and a2M inhibits
ADAMTS-4 and ADAMTS-5 by competitive inhibition upon
cleavage activity by the bait region of ADAMTS-4/-523, we in-
vestigated whether a2M is a also a substrate for ADAMTS-7
and ADAMTS-12. We ﬁrst examined the digestion of a2M by
ADAMTS-7 by incubation of 140 nM of a2Mwith various con-
centrations of puriﬁed recombinant ADAMTS-7 and resolved
the digests on Coomassie blue-stained SDS-PAGE. IntactFig. 4. Cleavage of a2M by ADAMTS-7 and ADAMTS-12. In vitro digestion
mM a2M was incubated in the absence or presence of various amount of
separated by 8% non-reduced SDS-PAGE and visualized by Coomassie
was incubated in the absence or presence of various amount of ADAMTS
by 6% non-reduced SDS-PAGE and visualized by Coomassie blue stain
resulted fragments,a2M in its tetramer form was detected at a molecular mass
of w700 kDa [Fig. 4(A), lane 1]. One major a2M cleavage
product with the apparent molecular weight of approximately
180 kDa was observed when 10 nM of ADAMTS-7 was ap-
plied and the intensity of this band strengthened gradually
with increasing concentrations of ADAMTS-7 [Fig. 4(A)];
a faint degradative fragment with the molecular weight of
105 kDawas observed usingADAMTS-7 at 430 nMor higher
[Fig. 4(B)]. A similar cleavage pattern of a2M was observed
using recombinant ADAMTS-12 [Fig. 4(C)].a2M INHIBITS ADAMTS-7- AND ADAMTS-12-MEDIATED COMP
DEGRADATIONSince a2M can be digested by ADAMTS-4 and ADAMTS-
5 and inhibits the cleavage of aggrecan by these en-
zymes23, we next examined whether a2M, as a substrate
of ADAMTS-7 and ADAMTS-12, also acts as an competi-
tive inhibitor of the degradation of COMP. ADAMTS-7 or
ADAMTS-12 at a concentration of 330 nM were preincu-
bated with various amounts of a2M for 2 h at 37
C. After
the preincubation COMP was added to a ﬁnal concentration
of 170 nM, and then the reactions were carried out for an-
other 2 h at 37C. The products were ﬁrst analyzed on
a non-reduced SDS-PAGE gel and visualized by Coomas-
sie blue staining [Fig. 5(A) and Fig. 6(A)]. Accompanyingassay of a2M by lower (A) or higher (B) amount of ADAMTS-7. 0.14-
ADAMTS-7, as indicated, for 2 h at 37C. The products were then
blue staining. (C) Digestion of a2M by ADAMTS-12. 0.10 mM a2M
-12, as indicated, for 2 h at 37C. The products were then separated
ing. Arrows 1, 2, 3 indicate the intact a2M, w180 kDa and 105 kDa
respectively.
Fig. 5. a2M inhibits ADAMTS-7-mediated COMP degradation in
a dose-dependent manner, assayed by Coomassie blue staining
(A) and Western blotting (B). 0.33-mM ADAMTS-7 was ﬁrst incu-
bated with increasing concentrations of a2M, as indicated, for 2 h
at 37C, then 0.17-mM COMP was added and allowed to incubate
for additional 2 h at 37C. The resulting products were analyzed by
8% non-reduced SDS-PAGE and visualized by either Coomassie
blue staining (A) or Western blotting with anti-COMP antibody
(B). Arrows 1, 2, 3 and 4 in (A) indicate the intact COMP, the
180-kDa fragment of a2M, the 110-kDa fragment of COMP and
the 105-kDa fragment of a2M, respectively. In panel (B), arrow
and arrowhead indicate intact COMP and its degradative fragment,
respectively. Lanes 1 and 2 indicate that anti-COMP antibody does
not cross-recognize neither intact a2M nor its 180-kDa degradative
fragment. Lanes 4e8 indicate that intact COMP was protected from
ADAMTS-7 cleavage by a2M in a dose-dependent manner.
Fig. 6. a2M inhibits ADAMTS-12-mediated COMP degradation in
a does-dependent manner, assayed by Coomassie blue staining
(A) and Western blotting (B). 0.20-mM ADAMTS-12 was ﬁrst incu-
bated with increasing concentrations of a2M, as indicated, for 2 h
at 37C, then 0.10-mM COMP was added and allowed to incubate
for an additional 2 h at 37C. The resultant products were analyzed
by 8% non-reduced SDS-PAGE and visualized by either Coomas-
sie blue staining (A) or Western blotting with anti-COMP antibody
(B). Arrows 1, 2, 3 and 4 in panel A indicate the intact COMP,
the 180-kDa fragment of a2M, the 110-kDa fragment of COMP
and the 105-kDa fragment of a2M, respectively. In panel B, the in-
tact COMP and its 110-kDa degradative fragment are indicated.
Lanes 1 and 2 indicate that anti-COMP antibody does not cross-react
with either intact a2M or its 180-kDa degradative fragment. Lanes
4e9 indicate that intact COMP was protected from ADAMTS-7
cleavage by a2M in a dose-dependent manner.
1418 Y. Luan et al.: Degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulinthe increase of a2M, the intensities of the180 kDa (arrow 2)
and 105 kDa (arrow 4) fragments of a2M became stronger,
whereas the 110-kDa COMP degradative fragment became
weaker and ﬁnally not visible (arrow 3) and the intact COMP
(arrow 1) band appeared [Fig. 5(A) and Fig. 6(A)]. Since
both intact a2M (700 kDa) and COMP (550 kDa) were re-
tained at the very top of the gel, we next performed Western
blotting with anti-COMP antibodies to determine whether
the top band (arrow 1) was COMP rather than a2M
[Fig. 5(B) and Fig. 6(B)]. Western blotting with anti-COMP
antibodies [these do not cross-react with a2M and its di-
gested products, lanes 1 and 2 of Fig. 5(B) and Fig. 6(B)]
clearly demonstrated that a2M efﬁciently protects COMP
from degradation by either ADAMTS-7 or ADAMTS-12.Discussion
ADAMTS family proteins have been implicated in the
pathogenesis of different diseases, including arthritis37e43.
We previously reported that ADAMTS-7 and ADAMTS-12,
two members in this family sharing similar domainorganization and structure, associated with and cleaved
COMP in the in vitro digestion system, and their levels
were signiﬁcantly elevated in the cartilage and synovium
of patients with arthritis9,10. The present study provides in-
sight into the importance of ADAMTS-7 and ADAMTS-12
in the degradation of COMP in the course of arthritis, since
the size of the COMP fragment produced by ADAMTS-7 or
ADAMTS-12 is similar to that of COMP degradative frag-
ments seen in OA patients (Fig. 1). Antibody blocking as-
says with cartilage explants have been widely used44e46.
Using this model we found that anti-ADAMTS-7 and/or
anti-ADAMTS-12 antibody dramatically inhibited COMP
degradation induced by TNF-a and IL-1b, two key cytokines
in the progression of arthritis that induce the expression of
ADAMTS-7 and ADAMTS-12 (Figs. 2 and 3). In addition,
both anti-ADAMTS-7 and anti-ADAMTS-12 antibodies did
not inhibit ADAMTS-4-mediated COMP digestion in an in
vitro assay (not shown). These data indicated that
ADAMTS-7 and ADAMTS-12 are important for the cyto-
kine-induced COMP degradation. The present study also
presents evidence that a2M is a novel substrate for
ADAMTS-7 and ADAMTS-12 (Figs. 4 and 5) and acts as
an inhibitor of COMP degradation mediated by these two
enzymes (Figs. 5 and 6).
Nineteen distinct human ADAMTS gene products have
been cloned and can be divided into ﬁve subgroups based
on their known functions12. The ﬁrst of the divisions,
1419Osteoarthritis and Cartilage Vol. 16, No. 11consisting of ADAMTS-1, ADAMTS-4, ADAMTS-5,
ADAMTS-8, ADAMTS-9, ADAMTS-15 and ADAMTS-20,
cleave aggrecan12. ADAMTS-1 also cleaves the related hya-
lectan versican at analogous sites and ADAMTS-4 has been
demonstrated to cleave brevican47. Among them, ADAMTS-
4 and ADAMTS-5 have been best characterized and
implicated in aggrecan degradation in OA16. ADAMTS-5 is
probably the major aggrecanase responsible for aggrecan
degradation in vivo41,48. ADAMTS-4 has been also shown
to cleave COMP as well as ﬁbromodulin and decorin49e51.
A second subgroup contains ADAMTS-2, ADAMTS-3 and
ADAMTS-14. ADAMTS-2 cleaves the amino peptides of
type I, type II and type III procollagens52,53, ADAMTS-3 has
since been identiﬁed as a type II procollagenN-propeptidase,
whose expression is about ﬁvefold that of ADAMTS-2 in car-
tilage54. ADAMTS-14 has been identiﬁed as a homologue of
ADAMTS-2, functioning as the major type I procollagen N-
propeptidase activity in tendon55. ADAMTS-13, a von Wille-
brand factor-cleaving protease, stands as one subgroup56,57.
ADAMTS-7 and ADAMTS-12 that speciﬁcally associate with
and degrade COMP represent another subgroup9,10,26,58.
And the remainingADAMTSmembers form a loosely deﬁned
subgroup with unknown functions12.
In addition to ADAMTS-7 and ADAMTS-12, ADAMTS-4
and several members of the family of matrix metalloprotei-
nases (MMPs), including interstitial collagenase (MMP-1),
collagenase-3 (MMP-13), stromelysin-1 (MMP-3), gelati-
nase-B (MMP-9), MMP-19, and enamelysin (MMP-20) also
digest puriﬁed COMP in vitro. Here we also show that, an ad-
ditional fragment (Fig. 1, small arrowhead) was observed in
OA samples that was absent in ADAMTS-12- and
ADAMTS-7-mediated COMP digestion, suggesting that ad-
ditional enzyme(s) may contribute to COMP degradation in
OA patients. In addition to COMP, a recent report revealed
that aggrecan was also a substrate of ADAMTS-1259, sug-
gesting that competitive substrate might lead to the enzyme
inhibition. In addition, several reports suggest that COMP
may function to stabilize the articular cartilage ECM by spe-
ciﬁc cation-dependent interactions with matrix components,
including collagen types II and IX, ﬁbronectin, aggrecan,
and matrilin-1, -3, and -432,60e63. Thus, it is conceivable
that the inhibition of COMPdegradationmay stabilize the car-
tilage matrix and in turn affect the degradation of the main
macromolecules, including collagens and aggrecan.
Full length a2M is approximately 185 kDa and forms a tet-
ramer. It may be cleaved by ADAMTS-4 and ADAMTS-5,
two major aggrecanases, and can inhibit their activities23.
In this study we demonstrated that a2M is also a substrate
for ADAMTS-7 and ADAMTS-12, two known COMP-associ-
ating and -degrading metalloproteinases (Figs. 4 and 5) and
prevents the degradation of COMP by these enzymes in
a does-dependent manner (Figs. 5 and 6). Degradation of
a2M by ADAMTS-7 and ADAMTS-12 gives rise to two frag-
ments, one major 180-kDa and one minor 105-kDa frag-
ment, suggesting that a2M may contain two cleavage
sites of ADAMTS-7 and ADAMTS-12 (Figs. 4 and 5). Tortor-
ella et al. have shown that ADAMTS-4 and ADAMTS-5
digested a2M at one major sensitive site and at additional
insensitive sites with much less efﬁciency23.
Evidence showing the importance of ADAMTS-7 and
ADAMTS-12 for the in vivo degradation of COMP, identiﬁ-
cation of a2M as a novel substrate for ADAMTS-7 and
ADAMTS-12, and subsequent characterization of its inhibi-
tory activities on the degradation of COMP by ADAMTS-7
and ADAMTS-12 signiﬁcantly extends our understanding
of the degradative events that occur in joint disorders.
These ﬁndings will also contribute to our ability to monitorthe biological and physical properties of cartilage ECM,
and provide us with promising therapeutic targets, including
a2M or its derivatives, for treating or preventing ECM
degeneration.Conﬂict of interest
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